The Delhi High Court has requested the Centre to present its position regarding a petition filed by a pharmaceutical company that challenges the government’s decision to ban the manufacture, sale, and distribution of certain Fixed Dose Combination (FDC) drugs for human use.
FDC drugs are those that contain a fixed ratio of two or more active pharmaceutical ingredients (APIs).
While issuing notices on three petitions filed by Glenmark Pharmaceuticals Ltd against the ban, the court has directed that the FDC drugs produced by the petitioners, which are already in the distribution channel, should not be withdrawn. It further ordered that no coercive measures be taken against the petitioners.
